Adial Pharmaceuticals (ADIL)
(Delayed Data from NSDQ)
$0.97 USD
-0.03 (-2.56%)
Updated Oct 1, 2024 03:59 PM ET
After-Market: $0.96 -0.01 (-1.38%) 7:58 PM ET
4-Sell of 5 4
F Value A Growth B Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ADIL 0.97 -0.03(-2.56%)
Will ADIL be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ADIL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADIL
Is Masimo (MASI) Outperforming Other Medical Stocks This Year?
All You Need to Know About Adial Pharmaceuticals, Inc. (ADIL) Rating Upgrade to Buy
ADIL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adial (ADIL) Shares Up 43% in the Past Week: Here's Why
Is Adial Pharmaceuticals (ADIL) Stock Outpacing Its Medical Peers This Year?
Adial Pharmaceuticals, Inc. (ADIL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Other News for ADIL
Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Adial Pharmaceuticals announces database lock in PK study of AD04
Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Maxim Group Sticks to Its Hold Rating for Adial Pharmaceuticals (ADIL)
Adial Pharmaceuticals reports Q2 results